Schedule 13G ownership disclosure

TRAVERE THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 89422G107

Event date: 2025-10-06

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Perceptive Advisors LLC

    Shares: 4,895,615 · Class: 5.5%

  • Joseph Edelman

    Shares: 4,895,615 · Class: 5.5%

  • Perceptive Life Sciences Master Fund, Ltd.

    Shares: 4,895,615 · Class: 5.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-238357
Form type
SCHEDULE 13G
Filer
PERCEPTIVE ADVISORS LLC
CIK
CIK 1224962
Filed
Oct 14, 2025
Reporting period
Oct 06, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub